FLT3 and acute myeloid leukemia: Concerning general characteristics and genetic features of t‐AML patients, as others, we reported more frequent abnormal karyotypes compared to de novo AML2, 15, 17, 18, 45, 46 and no difference in the incidence and distribution of mutated NPM1 and FLT3‐ITD between t‐AML and de novo AML.47